M
Mary Flack
Researcher at Boehringer Ingelheim
Publications - 11
Citations - 1138
Mary Flack is an academic researcher from Boehringer Ingelheim. The author has contributed to research in topics: Risankizumab & Ustekinumab. The author has an hindex of 7, co-authored 11 publications receiving 718 citations.
Papers
More filters
Journal ArticleDOI
Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials
Kenneth B. Gordon,Bruce Strober,Mark Lebwohl,Matthias Augustin,Andrew Blauvelt,Yves Poulin,Kim A. Papp,Howard Sofen,Lluís Puig,Peter Foley,Mamitaro Ohtsuki,Mary Flack,Ziqian Geng,Yihua Gu,Joaquin Mario Valdes,Elizabeth H.Z. Thompson,Hervé Bachelez +16 more
TL;DR: Co-primary endpoints were proportions of patients achieving a 90% improvement in the Psoriasis Area Severity Index (PASI 90) and a static Physician's Global Assessment (sPGA) score of 0 or 1 at week 16 (non-responder imputation).
Journal ArticleDOI
Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis.
Kim A. Papp,Andrew Blauvelt,Michael Bukhalo,Melinda Gooderham,James G. Krueger,Jean-Philippe Lacour,Alan Menter,Sandra Philipp,Howard Sofen,Stephen Tyring,Beate R. Berner,Sudha Visvanathan,Chandrasena Pamulapati,Nathan Bennett,Mary Flack,Paul Scholl,Steven J. Padula +16 more
TL;DR: In this phase 2 trial, selective blockade of interleukin‐23 with risankizumab was associated with clinical responses superior to those associated with ustekinumab, and this trial was not large enough or of long enough duration to draw conclusions about safety.
Journal ArticleDOI
Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled phase 3 trial.
Kristian Reich,Melinda Gooderham,Diamant Thaçi,Jeffrey J. Crowley,Caitriona Ryan,James G. Krueger,Tsen-Fang Tsai,Mary Flack,Yihua Gu,David A. Williams,Elizabeth H Z Thompson,Carle Paul +11 more
TL;DR: Risankizumab showed significantly greater efficacy than adalimumab in providing skin clearance in patients with moderate-to-severe plaque psoriasis, and safety analyses were done in the safety population.
Journal ArticleDOI
Efficacy and Safety of Continuous Risankizumab Therapy vs Treatment Withdrawal in Patients With Moderate to Severe Plaque Psoriasis: A Phase 3 Randomized Clinical Trial.
Andrew Blauvelt,Craig L. Leonardi,Melinda Gooderham,Kim A. Papp,Sandra Philipp,Jashin J. Wu,Atsuyuki Igarashi,Mary Flack,Ziqian Geng,Tianshuang Wu,Anne Camez,David A. Williams,Richard G. Langley +12 more
TL;DR: Findings support the use of 12-week risankizumab dosing as an efficacious and well-tolerated regimen for maintenance of clinical efficacy in patients with moderate to severe plaque psoriasis.
Journal ArticleDOI
Efficacy and safety of risankizumab in Japanese patients with moderate to severe plaque psoriasis: Results from the SustaIMM phase 2/3 trial.
Mamitaro Ohtsuki,Hideki Fujita,Mitsunori Watanabe,Keiko Suzaki,Mary Flack,Xin Huang,Susumu Kitamura,Joaquin Mario Valdes,Atsuyuki Igarashi +8 more
TL;DR: Both doses of risankizumab were superior to placebo in treating patients with moderate to severe plaque psoriasis and the safety profile was consistent with previous risankIZumab trials, with no new or unexpected safety findings.